Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.
Business Of Biotech
00:00
The Why and How of the Alt Event Ends Event Merger
I want to revisit sort of the why behind the merger and how things went. It's been tough during this, you know, post COVID time, if you want to call it that was supply chain. There's still difficulties there, but the team has done a great job tackling those issues. I look forward to us having our own manufacturing facility to be able to increase the output of a thymic.
Transcript
Play full episode
